Table 1.
Correlates of WA1- and BA-neutralizing Ab response following booster vaccination.
| WA1 neutralization | BA (Omicron) neutralization | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| All patients (N = 187) | NC negative (N = 65) | All patients (N = 187) | NC negative (N = 65) | ||||||||
| Covariate | Level | N | Odds ratio (95% CI) | P value | N | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value |
| Sex | Female | 92 | 1.73 (0.72–4.18) | 0.223 | 31 | 6.04 (1.21–30.28) | 0.029 | 1.00 (0.55–1.81) | 0.991 | 1.78 (0.66–4.78) | 0.252 |
| Male | 95 | — | — | 34 | — | — | — | — | — | — | |
| Racea | Black | 68 | 1.53 (0.60–3.90) | 0.376 | 24 | 0.86 (0.24–3.09) | 0.815 | 1.07 (0.57–2.00) | 0.834 | 0.47 (0.16–1.32) | 0.150 |
| Other | 114 | — | — | 38 | — | — | — | — | — | — | |
| Age ≤65 | Yes | 108 | 0.65 (0.26–1.60) | 0.347 | 34 | 1.69 (0.48–6.02) | 0.417 | 1.07 (0.58–1.96) | 0.830 | 0.93 (0.35–2.46) | 0.878 |
| No | 79 | — | — | 31 | — | — | — | — | — | — | |
| Prior LOT (>2) | Yes | 46 | 0.46 (0.18–1.15) | 0.081 | 21 | 0.36 (0.09–1.35) | 0.130 | 0.42 (0.21–0.84) | 0.013 | 0.27 (0.09–0.82) | 0.021 |
| No | 135 | — | — | 40 | — | — | — | — | — | — | |
| Prior SARS-CoV-2 exposure | Positive | 40 | 2.79 (0.74–10.59) | 0.131 | 2.00 (0.87–4.60) | 0.103 | |||||
| Negative | 65 | — | — | — | — | ||||||
| IgG ≤400 | Yes | 48 | 0.35 (0.14–0.84) | 0.019 | 21 | 0.26 (0.07–0.94) | 0.040 | 0.81 (0.41–1.58) | 0.53 | 0.69 (0.24–1.96) | 0.487 |
| No | 139 | — | — | 44 | — | — | — | — | — | — | |
| Vaccine type | Moderna | 54 | 1.85 (0.57–5.97) | 0.306 | 19 | 1.57 (0.27–9.04) | 0.611 | 1.43 (0.71–2.87) | 0.319 | 1.71 (0.54–5.48) | 0.363 |
| Pfizer | 101 | — | — | 32 | — | — | — | — | — | — | |
| Anti-CD38 | Yes | 60 | 0.76 (0.31–1.85) | 0.599 | 21 | 1.54 (0.37–6.41) | 0.551 | 0.85 (0.45–1.61) | 0.624 | 1.22 (0.43–3.47) | 0.713 |
| No | 127 | — | — | 44 | — | — | — | — | — | — | |
| Len maintenance | Yes | 44 | 8.24 (1.08–62.82) | 0.042 | 14 | 3.57 (0.42–30.40) | 0.243 | 1.93 (0.90–4.13) | 0.107 | 4.12 (1.03–16.56) | 0.046 |
| No | 143 | — | — | 51 | — | — | — | — | — | — | |
| Anti-BCMAb,c | Yes | 6 | 0.06 (0.01–0.36) | 0.002 | 4 | 0.06 (0.01–0.62) | 0.018 | 0.10 (0.01–0.91) | 0.041 | ||
| No | 181 | — | — | 61 | — | — | — | — | |||
NOTE: Anti-BCMA could not be evaluated for Omicron neutralization (NC negative cohort) due to inestimable ORs.
Abbreviations: LOT, lines of therapy; IgG, immunoglobulin G.
aAmong the n = 114 with other race, 110 were White, 2 Asian, 1 Native American, and 1 Native Hawaiian or Pacific Islander.
b P < 0.05 on MVA for WT neutralization (all).
c P < 0.05 on MVA for WT neutralization (NC negative).